• Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Unspecified (from parent cell line).
  
• Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (from parent cell line).
  
• Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line).
  

PubMed=1319859; DOI=10.1007/BF00133561
Taniguchi S., Iwamura T., Katsuki T.
Correlation between spontaneous metastatic potential and type I collagenolytic activity in a human pancreatic cancer cell line (SUIT-2) and sublines.
Clin. Exp. Metastasis 10:259-266(1992)

PubMed=1391733; DOI=10.1111/j.1440-1746.1992.tb01030.x
Iwamura T., Taniguchi S., Kitamura N., Yamanari H., Kojima A., Hidaka K., Setoguchi T., Katsuki T.
Correlation between CA19-9 production in vitro and histological grades of differentiation in vivo in clones isolated from a human pancreatic cancer cell line (SUIT-2).
J. Gastroenterol. Hepatol. 7:512-519(1992)

PubMed=10027404; DOI=10.1016/S0002-9440(10)65292-3; PMCID=PMC1849991
Kataoka H., Uchino H., Iwamura T., Seiki M., Nabeshima K., Koono M.
Enhanced tumor growth and invasiveness in vivo by a carboxyl-terminal fragment of alpha1-proteinase inhibitor generated by matrix metalloproteinases: a possible modulatory role in natural killer cytotoxicity.
Am. J. Pathol. 154:457-468(1999)

PubMed=11854916; DOI=10.3748/wjg.v7.i6.855; PMCID=PMC4695609
Liu B., Staren E., Iwamura T., Appert H., Howard J.
Taxotere resistance in SUIT. Taxotere resistance in pancreatic carcinoma cell line SUIT 2 and its sublines.
World J. Gastroenterol. 7:855-859(2001)